Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

P. Ravi, S. Kumar, W. Gonsalves, F. Buadi, M. Q. Lacy, R. S. Go, A. Dispenzieri, P. Kapoor, J. A. Lust, D. Dingli, Y. Lin, S. J. Russell, N. Leung, M. A. Gertz, R. A. Kyle, P. L. Bergsagel, S. V. Rajkumar

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone (RD), bortezomib and dexamethasone (VD), bortezomib, cyclophosphamide and dexamethasone (VCD) or bortezomib, lenalidomide and dexamethasone (VRD) for newly diagnosed MM at our institution between 2000 and 2013, and who had available data on absolute lymphocyte count (ALC) and quantitative uninvolved Ig at baseline and at the end of four cycles of therapy. Changes in ALC and uninvolved Ig were significantly different across treatments, with VCD and HD-DEX producing reductions in uninvolved Ig, and RD, VD and VRD leading to increases in uninvolved Ig. In addition, treatment with RD, VD and VRD was independently associated with higher odds of achieving a ⩾25% increase in or normalization of the primary uninvolved Ig on multivariate analysis. Although achievement of a humoral response in the primary uninvolved Ig was associated with a higher odds of achieving VGPR or better after four cycles of therapy, it was not associated with improved overall survival. These data highlight the different mechanisms of action of MM drugs and point toward a possible role for the use of VCD in treating antibody-mediated autoimmune disease.

Original languageEnglish (US)
Pages (from-to)e569
JournalBlood cancer journal
Volume7
Issue number6
DOIs
StatePublished - Jun 16 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this